BR112015030140A2 - forma de dosagem farmacêutica sólida para liberação de pelo menos um ingrediente farmacêutico ativo na cavidade oral - Google Patents
forma de dosagem farmacêutica sólida para liberação de pelo menos um ingrediente farmacêutico ativo na cavidade oralInfo
- Publication number
- BR112015030140A2 BR112015030140A2 BR112015030140A BR112015030140A BR112015030140A2 BR 112015030140 A2 BR112015030140 A2 BR 112015030140A2 BR 112015030140 A BR112015030140 A BR 112015030140A BR 112015030140 A BR112015030140 A BR 112015030140A BR 112015030140 A2 BR112015030140 A2 BR 112015030140A2
- Authority
- BR
- Brazil
- Prior art keywords
- dosage form
- releasing
- oral cavity
- pharmaceutical dosage
- solid pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Medicinal Preparation (AREA)
Abstract
resumo patente de invenção "forma de dosagem farmacêutica sólida para liberação de pelo menos um ingrediente farmacêutico ativo na cavidade oral". trata-se de forma de dosagem farmacêutica sólida para a liberação de pelo menos um ingrediente farmacêutico ativo (api, em inglês) na cavidade oral compreendendo um núcleo revestido por pelo menos um revestimento de filme. o núcleo compreende pelo menos um api. uma ou mais sensações organolepticamente perturbadoras induzidas por um ou vários apis e/ou componentes inativos da forma de dosagem farmacêutica sólida é/são reduzida(s) pelos constituintes do dito revestimento de filme. os ditos constituintes compreendem pelo menos um polímero formador de filme e pelo menos um agente flavorizante ou pelo menos um adoçante.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE1300404 | 2013-06-03 | ||
PCT/SE2014/050670 WO2014196916A1 (en) | 2013-06-03 | 2014-06-02 | Solid pharmaceutical dosage form for release of at least one active pharmaceutical ingredient in the oral cavity |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112015030140A2 true BR112015030140A2 (pt) | 2017-07-25 |
Family
ID=52008428
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015030140A BR112015030140A2 (pt) | 2013-06-03 | 2014-06-02 | forma de dosagem farmacêutica sólida para liberação de pelo menos um ingrediente farmacêutico ativo na cavidade oral |
Country Status (13)
Country | Link |
---|---|
US (2) | US20160095818A1 (pt) |
EP (1) | EP3003285B1 (pt) |
CN (1) | CN105307645A (pt) |
AU (1) | AU2014275543B2 (pt) |
BR (1) | BR112015030140A2 (pt) |
CA (1) | CA2914379C (pt) |
DK (1) | DK3003285T3 (pt) |
ES (1) | ES2908977T3 (pt) |
HK (1) | HK1218884A1 (pt) |
PL (1) | PL3003285T3 (pt) |
PT (1) | PT3003285T (pt) |
RU (1) | RU2015156033A (pt) |
WO (1) | WO2014196916A1 (pt) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9993558B2 (en) | 2004-10-01 | 2018-06-12 | Ramscor, Inc. | Sustained release eye drop formulations |
AU2014268434B2 (en) | 2013-05-24 | 2018-11-22 | Icon Bioscience, Inc. | Use of sustained release dexamethasone in post-cataract surgery inflammation |
US9855227B2 (en) | 2015-12-18 | 2018-01-02 | The Procter & Gamble Company | Quick dissolving diphenhydramine oral dosage form |
CN105833278B (zh) * | 2016-04-25 | 2018-05-08 | 北京嘉安医疗器械科技有限公司 | 用于治疗口腔干燥和口腔疾病的组合物 |
CN105919982A (zh) * | 2016-06-30 | 2016-09-07 | 合肥华方医药科技有限公司 | 一种消旋卡多曲口腔速溶膜及其制备方法 |
HUE055173T2 (hu) | 2017-02-01 | 2021-11-29 | Johnson & Johnson Consumer Inc | Gyógycukorka |
EP3634387B1 (en) | 2017-05-22 | 2024-01-17 | Johnson & Johnson Consumer Inc. | Lozenge dosage form |
RU2749902C2 (ru) * | 2018-10-31 | 2021-06-18 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Фармацевтическая композиция для лечения инфекционно-воспалительных заболеваний |
US11179331B1 (en) | 2020-04-21 | 2021-11-23 | Cure Pharmaceutcai Holding Corp | Oral soluble film containing sildenafil citrate |
CN113413388B (zh) * | 2021-06-30 | 2022-11-15 | 上海奥全生物医药科技有限公司 | 含有枸橼酸西地那非的药物组合物、制备方法及其应用 |
WO2023028179A1 (en) * | 2021-08-25 | 2023-03-02 | Get-Grin Inc. | Systems and methods for monitoring a tooth whitening regimen |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE8310750U1 (de) | 1983-04-12 | 1984-07-19 | Geppert, Helmut, 5162 Niederzier | Spannvorrichtung fuer einen ueber einen eine treibwalze antreibenden getriebemotor angetriebenen bandfoerderer |
US4678516A (en) * | 1984-10-09 | 1987-07-07 | The Dow Chemical Company | Sustained release dosage form based on highly plasticized cellulose ether gels |
US5002769A (en) * | 1987-03-13 | 1991-03-26 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Compositions for the sustained-release of chlorhexidine |
GB8928196D0 (en) * | 1989-12-13 | 1990-02-14 | Merrell Dow Pharmaceuticals Li | Pharmaceutical lozenges |
US5098715A (en) * | 1990-12-20 | 1992-03-24 | Burroughs Wellcome Co. | Flavored film-coated tablet |
US5614207A (en) * | 1995-06-30 | 1997-03-25 | Mcneil-Ppc, Inc. | Dry mouth lozenge |
AU733140B2 (en) * | 1998-09-29 | 2001-05-10 | Hitachi Limited | A friction stir welding method |
US20020119196A1 (en) * | 2000-12-21 | 2002-08-29 | Narendra Parikh | Texture masked particles containing an active ingredient |
US8980334B2 (en) * | 2001-02-28 | 2015-03-17 | Axiomedic Ltd. | Double-layered absorbable solid compositions for the topical treatment of oral mucosal disorders |
US6596313B2 (en) * | 2001-08-06 | 2003-07-22 | The Quigley Corporation | Nutritional supplement and methods of using it |
EP1656117A1 (en) | 2003-08-11 | 2006-05-17 | Merck Frosst Canada Ltd. | Flavored taste-masked pharmaceutical formulation made using a one-step coating process |
GB0330255D0 (en) * | 2003-12-31 | 2004-02-04 | Vectura Ltd | Multiparticulate formulations for oral delivery |
US20070196474A1 (en) * | 2004-04-30 | 2007-08-23 | Withiam Michael C | Rapidly disintegrating low friability tablets comprising calcium carbonate |
US8238554B2 (en) * | 2004-07-22 | 2012-08-07 | Sanyo Electric Co., Ltd. | Method for transmission/reception of contents usage right information in encrypted form, and device thereof |
DE102004041850A1 (de) | 2004-08-27 | 2006-03-02 | Basf Ag | Verfahren zur Herstellung von C5-Aldehyden und Propen aus einem 1-Buten- und 2-Buten-haltigen C4-Strom |
US8323683B2 (en) * | 2005-05-18 | 2012-12-04 | Mcneil-Ppc, Inc. | Flavoring of drug-containing chewing gums |
WO2007046890A1 (en) * | 2005-10-14 | 2007-04-26 | Effrx, Inc. | Lozenge for treatment of dry mouth and related conditions |
NZ572106A (en) * | 2006-03-31 | 2010-12-24 | Rubicon Res Private Ltd | Directly compressible composite for orally disintegrating tablets |
US20080031927A1 (en) * | 2006-07-11 | 2008-02-07 | Catani Steven J | Solid oral dosage vitamin and mineral compositions |
US20100247453A1 (en) * | 2006-07-12 | 2010-09-30 | Thomas L. Jones | Composition and method of treating a sore throat |
WO2009078034A2 (en) * | 2007-11-26 | 2009-06-25 | Rubicon Research Private Limited | Oral disintegrating tablets of ropinirole hydrochloride |
BRPI0820997A2 (pt) * | 2007-12-10 | 2014-12-23 | Eurand Inc | Comprimidos de desintegração oral compreendendo difenidramina. |
WO2009078037A2 (en) * | 2007-12-17 | 2009-06-25 | Gland Pharma Limited | Novel process for the preparation of iron sucrose complex |
US20100028512A1 (en) * | 2008-03-28 | 2010-02-04 | The Coca-Cola Company | Bio-based polyethylene terephthalate packaging and method of making thereof |
WO2010046933A2 (en) | 2008-10-22 | 2010-04-29 | Rubicon Research Private Limited | Pharmaceutical compositions of taste-masked linezolid |
WO2011030351A2 (en) * | 2009-09-03 | 2011-03-17 | Rubicon Research Private Limited | Taste - masked pharmaceutical compositions |
US9012384B2 (en) * | 2010-07-30 | 2015-04-21 | Chevron U.S.A. Inc. | Method of preparing greases |
JP6521564B2 (ja) | 2010-12-22 | 2019-05-29 | ビーエーエスエフ ソシエタス・ヨーロピアBasf Se | 速崩性の固体被覆剤形 |
US8715729B2 (en) * | 2010-12-22 | 2014-05-06 | Basf Se | Rapidly disintegrating, solid coated dosage form |
US20120288591A1 (en) * | 2011-05-13 | 2012-11-15 | The Hershey Company | Film coated confectionery product |
EA034288B1 (ru) * | 2011-05-13 | 2020-01-24 | Эб Ип Хибритабс Б.В. | Система доставки лекарственного средства |
US20130177646A1 (en) * | 2012-01-05 | 2013-07-11 | Mcneil Ab | Solid Nicotine-Comprising Dosage Form with Reduced Organoleptic Disturbance |
-
2014
- 2014-06-02 EP EP14808018.7A patent/EP3003285B1/en active Active
- 2014-06-02 WO PCT/SE2014/050670 patent/WO2014196916A1/en active Application Filing
- 2014-06-02 PT PT148080187T patent/PT3003285T/pt unknown
- 2014-06-02 CN CN201480031819.2A patent/CN105307645A/zh active Pending
- 2014-06-02 CA CA2914379A patent/CA2914379C/en active Active
- 2014-06-02 ES ES14808018T patent/ES2908977T3/es active Active
- 2014-06-02 US US14/892,286 patent/US20160095818A1/en not_active Abandoned
- 2014-06-02 BR BR112015030140A patent/BR112015030140A2/pt not_active Application Discontinuation
- 2014-06-02 DK DK14808018.7T patent/DK3003285T3/da active
- 2014-06-02 RU RU2015156033A patent/RU2015156033A/ru unknown
- 2014-06-02 PL PL14808018T patent/PL3003285T3/pl unknown
- 2014-06-02 AU AU2014275543A patent/AU2014275543B2/en active Active
-
2016
- 2016-06-17 HK HK16106989.2A patent/HK1218884A1/zh unknown
-
2018
- 2018-08-07 US US16/056,613 patent/US20180338924A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
HK1218884A1 (zh) | 2017-03-17 |
ES2908977T3 (es) | 2022-05-04 |
US20180338924A1 (en) | 2018-11-29 |
PT3003285T (pt) | 2022-05-02 |
RU2015156033A3 (pt) | 2018-05-03 |
EP3003285B1 (en) | 2022-02-16 |
DK3003285T3 (en) | 2022-04-04 |
RU2015156033A (ru) | 2017-07-13 |
EP3003285A4 (en) | 2016-11-23 |
PL3003285T3 (pl) | 2022-06-20 |
EP3003285A1 (en) | 2016-04-13 |
CA2914379C (en) | 2021-03-23 |
CA2914379A1 (en) | 2014-12-11 |
CN105307645A (zh) | 2016-02-03 |
US20160095818A1 (en) | 2016-04-07 |
AU2014275543B2 (en) | 2019-09-12 |
AU2014275543A1 (en) | 2015-12-10 |
WO2014196916A1 (en) | 2014-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015030140A2 (pt) | forma de dosagem farmacêutica sólida para liberação de pelo menos um ingrediente farmacêutico ativo na cavidade oral | |
BR112014016624A8 (pt) | forma de dosagem sólida compreendendo nicotina com perturbação organoléptica reduzida | |
BR112018076601A2 (pt) | formulação farmacêutica oral, métodos para tratar um paciente, e, uso de uma formulação | |
BR112018010234A2 (pt) | spray formador de película tópica | |
BR112013031406A2 (pt) | forma de dosagem oral comestível em tira ou disco contendo resina de troca iônica para mascarar o sabor | |
BR112018067586A2 (pt) | composição administrável oralmente | |
BR112013004416A2 (pt) | agente terapêutico para enfisema pulmonar | |
BRPI0915386B8 (pt) | Dispositivo para aplicação de um agente ativo através de mucosa | |
CL2018001686A1 (es) | Métodos y composiciones particularmente para el tratamiento del trastorno por déficit de atención (divisional solicitud 201701026) | |
CL2015002733A1 (es) | Composición farmacéutica de clorhidrato de s-cetamina. | |
BR112015019430A2 (pt) | composição farmacêutica formadora de película para curar ferimento e método para a sua preparação | |
AR094374A1 (es) | Composiciones y métodos para el tratamiento de trastornos metabólicos | |
MX2018001584A (es) | Composiciones de solución sólida para aines. | |
BR112015031417A2 (pt) | forma de dosagem farmacêutica, composição farmacêutica, métodos para tratamento de um paciente com necessidade de cisteamina e para preparo de uma forma de dosagem | |
BR112015017251A2 (pt) | composições farmacêuticas compreendendo doadores de nitroxil | |
BR112014014795A2 (pt) | sistema de pélete de multiunidade de liberação imediata | |
CL2016002560A1 (es) | Forma de dosificación farmacéutica sólida oral que comprende siponimod, un agente protector de la humedad y opcionalmente un excipiente farmacéutico; procedimiento de preparación. | |
MX2018012800A (es) | Administracion de metabolitos de berberina. | |
BR112018068116A2 (pt) | película transmucosal para administração de montelucaste | |
CO6400184A2 (es) | Formulaciones galénicas de compuestos orgánicos | |
BR112015020237A2 (pt) | comprimido com revestimento entérico | |
CO2018009543A2 (es) | Composición farmacéutica de liberación prolongada que comprende cisteamina o sal de la misma | |
AR096223A1 (es) | Pastilla de nicotina para administración oral | |
BR112014029079A2 (pt) | composição farmacêutica para administração oral | |
CO2018002046A2 (es) | Nueva composición oral de libreación retardada dual de dexlansoprazol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B07C | Technical examination (opinion): republication [chapter 7.3 patent gazette] |
Free format text: REFERENTE AO DESPACHO 7.5 NOTIFICADO NA RPI 2530, DE 02/07/2019. |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |